STORY -- A Pivotal Autism Clinical Trial Utilizing Illumina Next Generation Sequencing

2013年6月6日

SynapDx is developing a test to shorten the time from suspicion of autism to diagnosis. They chose Illumina next-generation sequencing technology as the platform for designing performance characteristics and be the basis for their roll out as a diagnostic test. Their clinical trial, a 600-patient study called STORY, is currently in progress.

この記事を共有します